ARCH Venture Partners

About

Portfolio · 1

Chiasma

Oral Therapeutic Options for Patients with Rare Diseases

3 rounds $147.5M committed Latest: 2015-02

Investment activity

1 portfolio exit on record.

Funds · 1

• 13 — $3B Sep 2024

Q&A

What is ARCH Venture Partners' primary investment focus?

ARCH Venture Partners specializes in early-stage investments in life science innovations aimed at preventing, detecting, and curing diseases.

When was ARCH Venture Partners founded?

ARCH Venture Partners was founded in 1986.

What is a notable recent fund raised by ARCH Venture Partners?

In September 2024, ARCH Venture Partners raised Fund 13 with an amount of $3 billion.

Can you name a key exit for ARCH Venture Partners?

ARCH Venture Partners had an exit in July 2015 with Chiasma, which went public on NASDAQ with a valuation of $562 million.

What is ARCH Venture Partners' most represented sector in its portfolio?

Health Tech & Life Sciences is the most represented sector in ARCH Venture Partners' portfolio.

What investment stages does ARCH Venture Partners typically engage in?

ARCH Venture Partners typically invests in Pre-Seed, Seed, and A Round stages.

What is the typical investment range for ARCH Venture Partners?

ARCH Venture Partners' investment range is between $33.5 million and $70 million.